News Sanofi linked to takeover bid for Ocular Therapeutix Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year.
News Ocugen shares fall, despite positive eye disorder trial A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.
News Autonomous AI can spot cognitive decline in medical notes An AI that screens for early cognitive impairment by sifting through routine clinical documents has shown its value in a real-world evaluation.
News Trump's affordability plan arrives, built around MFN pricing Trump has finally delivered his healthcare proposals, but it seems the 'concept of a plan' promised for many years remains pretty much just that.
News J&J builds case for earlier Tecvayli use in multiple myeloma Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.
News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.